title: Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients.
abstract: Hypercholesterolemia (type II hyperlipidemia) after cardiac transplantation is common and may play a role in the accelerated rate of coronary atherosclerosis seen following the procedure. However, conventional cholesterol-lowering drugs are either ineffective or contraindicated for use in transplant recipients. The presence of type II hyperlipidemia was identified in 11 cardiac transplant recipients during a mean follow-up period of 15 months (range 3 to 41) after transplantation. Lovastatin, at an initial dosage of 20 mg/day, was administered for a period of 1 year. The maximal dosage of lovastatin was 60 mg/day. All patients received maintenance dosages of immunosuppressive agents, including cyclosporine-A, prednisone and, in some instances, azathioprine. Lipid profiles, hepatic transaminases, serum creatinine, creatine kinase and cyclosporine-A serum trough levels were measured quarterly. Total cholesterol decreased by 27% (354 +/- 50 vs 258 +/- 36 mg/dl, p less than 0.01) after 3 months and remained stable thereafter. Similarly, low density lipoprotein cholesterol decreased by 34% (221 +/- 51 vs 146 +/- 40 mg/dl, p less than 0.01) after 3 months and remained constant. Triglycerides, high density lipoprotein, hepatic transaminases, creatinine, creatine kinase and trough cyclosporine-A levels remained stable during the 1-year follow-up period. Lovastatin was uniformly well tolerated in this study group. When given in modest dosages, lovastatin appears to be a safe, effective and well-tolerated therapy for hypercholesterolemia in cardiac transplant recipients.
authors.affiliation: Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
authors.forename: P C
authors.initials: PC
authors.lastname: Kuo
authors.forename: J M
authors.initials: JM
authors.lastname: Kirshenbaum
authors.forename: J
authors.initials: J
authors.lastname: Gordon
authors.forename: G
authors.initials: G
authors.lastname: Laffel
authors.forename: P
authors.initials: P
authors.lastname: Young
authors.forename: V J
authors.initials: VJ
authors.lastname: DiSesa
authors.forename: G H
authors.initials: GH
authors.lastname: Mudge
authors.forename: D E
authors.initials: DE
authors.lastname: Vaughan
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D008078:Cholesterol, LDL; D007166:Immunosuppressive Agents; D002784:Cholesterol; D008148:Lovastatin